Drug class
Somatostatin analogue; diagnostic radiopharmaceutical precursor (68Ga-edotreotide PET)
Mechanism of action
After radiolabelling with gallium-68, edotreotide binds somatostatin receptors with high affinity, mainly SSTR2 and to a lesser extent SSTR5, enabling PET localisation of somatostatin-receptor-expressing lesions.
General use cases
- Diagnostic PET imaging of somatostatin-receptor overexpression in adults with confirmed or suspected well-differentiated gastro-enteropancreatic neuroendocrine tumours, for localisation of primary tumours and metastases; edotreotide kit requires radiolabelling before administration
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
